Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of single 45 mg dose of primaquine in G6PD-deficient healthy volunteers in Thailand
TCTR20220317004Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of primaquine in vivax malaria, sponsored by University of Oxford. Primary endpoint: Tolerability and safety of single 45 mg dose of primaquine. Started Jun 2022; status: completed.
02
Drugs
primaquine
03
Conditions
vivax malaria
Beyond the preview
Go deeper on TCTR20220317004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220317004.